## 7-5/2015/EU/WC-0350

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated: 17-01-2025

To,

M/s. Shashi Phytochemical Industries, 329, Old Industrial Area, Alwar-301001, Rajasthan, India

**SUB:**- Written Confirmation of M/s. Shashi Phytochemical Industries, 329, Old Industrial Area, Alwar-301001, Rajasthan, India, as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/RE/2024/8936 dated 31.08.2024 submitted to CDSCO, DDC(I), North Zone, and the recommendation received from DDC(I), North Zone, on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- 1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- The manufacturer is subject to regular, strict and transparent controls and to the
  effective enforcement of Good Manufacturing Practice, including repeated and
  unannounced inspections, so as to ensure a protection of public health equivalent to
  that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
- 9. The manufacturer is required to comply to the provision of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
encontra a	ere est un <del>e</del> spatica de	17-01-2025	01.02.2028
01	10	17-01-2025	01.02.2028

Yours faithfully,

(Ranga Chandrashekar)
Joint Drugs Controller (India)

Chandrachener

चंद्रशेखर रंगा/Chandrashekar Ranga संयुक्त औषधि निवंत्रक (भारत) / Joint Drugs Controller(India) केंद्रीय औषधि मानक निवंत्रण संगठन (मुख्यात्व), स्वास्थ्य सेवा महानिदेशालय C.D.S.C.O(HQ), Die. General of Health Services स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare महासीह कहा, बेटला ऐंद, वंहिल्ली-110002 / FDA Bhavan, Koda Road, New Delhi-110002



## **CERTIFICATE NO.:**

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: M/s. Shashi Phytochemical Industries,

329, Old Industrial Area, Alwar-301001.

Rajasthan, India

2. Manufacturer's licence number: Raj/1259 & Raj/1260

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

As per list enclosed as Annexure

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU(= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 08.11.2024

The Written Confirmation remains valid until: 01.02.2028

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation

FDA Bhawan, Kotla Road, New Delhi- 110 002, India

Name and function of responsible person:

E-mail:

Telephone no.:

chandrowner

Fax no.:

Sh. Ranga Chandrashekar, Joint Drugs Controller (India) ranga.cs@cdsco.nic.in.

+91-11-23236965

+91-11-23236973

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga

संयुक्त औषिः नियंत्रक (भारत) / Joint Drugs Controller(India) केंद्रीय औषिः मानक ल्यित्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय

C.D.S.C.O(HQ), Die. General of Health Services स्वास्थ्य और सीवार कल्याण पत्रालय (Mussicy of Health and Mussicy of Health Services Stamp of the authority and date

Early Welfare.

17 JAN 2025





**CERTIFICATE NO.:** 

Annexure-01

WC-0350

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Shashi Phytochemical Industries, 329, Old Industrial Area, Alwar-301001, Rajasthan, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Senna Leaf dry extract, Standardized EP	Manufacturing & Packing
2.	Sennosides USP	Manufacturing & Packing
3.	Senna Dry Extract IP	Manufacturing & Packing
4.	Calcium Sennosides (A&B) 10%, 20% & 60% IH	Manufacturing & Packing
5.	Senna Leaf IP/EP/USP	Manufacturing & Packing
6.	Senna Pods IP/USP/Ph.Eur./BP	Manufacturing & Packing
7.	Senna Pods, Tinnevelly EP/BP	Manufacturing & Packing
8.	Senna Leaflet BP/Ph.Eur	Manufacturing & Packing
9.	Senna Leaflet Dry Extract Ph.Eur./BP (Standardised)	Manufacturing & Packing
10.	Berberine Hydrochloride JP	Manufacturing & Packing

ITEM(S) TEN (10) ONLY

The Written Confirmation remains valid until: 01.02.2028

Signature

चंद्रशेखर रेगा/Chandrashekar Ranga संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India) केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय C.D.S.C.O(HQ), Dtc. General of Health Services स्वास्थ्य और वरिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare एक.डी.ए भवन, बोरना गोड, यह दिल्ली-110002 / FDA Hhrvan Kints Book Manager

Chandratherer

Stamp of the authority and date

1 7 JAN 2025